328233-08-5

Basic information

• Product Name: trans-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxylic acid
• Synonyms: TRANS-3''-OXO-SPIRO[CYCLOHEXANE-1,1''(3''H)-ISOBENZOFURAN]-4-CARBOXYLIC ACID
• CAS NO: 328233-08-5
• Molecular Formula: C₁₄H₁₄O₄
• Molecular Weight: 246.261
• Mol File: 328233-08-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 504.765 °C at 760 mmHg
• Flash Point: 198.188 °C
• Appearance: /
• Density: 1.35
• CAS DataBase Reference: trans-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: trans-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxylic acid(328233-08-5)
• EPA Substance Registry System: trans-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxylic acid(328233-08-5)

Safety Data

• Hazardous Substances Data: 328233-08-5(Hazardous Substances Data)

Usage

General Description

Trans-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxylic acid is a chemical compound with a complex molecular structure. It belongs to the spiro compound family, containing a cyclohexane ring and an isobenzofuran ring. The presence of an oxo group at the 3' position and a carboxylic acid group at the 4 position confers unique chemical properties to this compound. It may have potential applications in pharmacology, organic synthesis, or material science due to its intriguing structure and functional groups. However, further research is necessary to fully understand the properties and potential uses of trans-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxylic acid.

Upstream product

• 20759-14-2 ruthenium(III) chloride hydrate 
• 328233-07-4 4-hydroxymethylspiro[cyclohexane-1,1'(3'H)-isobenzofuran]-3'-one 
• 1075736-35-4 trans-3-oxo-3H-spiro[2-benzofuran-1,1'-cyclohexane]-4'-carbonitrile 

Downstream Products

• 1075752-97-4 C₂₀H₂₀N₂O₃ 
• 1078728-32-1 C₂₂H₂₂N₆O₃ 
• 1078728-27-4 C₂₀H₁₈Cl₂N₂O₃ 
• 1078728-23-0 C₂₆H₂₃FN₂O₃ 
• 640271-64-3 C₂₆H₂₁FN₂O₂ 
• 1078728-29-6 C₂₆H₂₃ClN₂O₃ 
• 1078728-07-0 C₂₆H₂₁ClN₂O₂ 
• 1078728-30-9 C₂₂H₂₁ClN₂O₅ 
• 1078728-31-0 C₂₂H₂₁ClN₂O₅ 
• 1078728-25-2 C₂₅H₂₃N₃O₃ 
• 1078728-26-3 C₂₅H₂₃N₃O₃ 
• 640271-47-2 C₂₂H₂₂N₂O₅ 
• 1078728-24-1 C₂₇H₂₄N₂O₄ 

Relevant articles and documents

Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist

A series of trans-3-oxospiro[(aza)isobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide derivatives were synthesized to identify potent NPY Y5 receptor antagonists. Of the compounds, 21j showed high Y5 binding affinity, metabolic stability and brain and cerebrospinal fluid (CSF) penetration, and low susceptibility to P-glycoprotein transporters. Oral administration of 21j significantly inhibited the Y5 agonist-induced food intake in rats with a minimum effective dose of 1 mg/kg. This compound was selected for proof-of-concept studies in human clinical trials.

Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists

Syntheses and structure-activity relationships of a novel class of 2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists are described. Optimization of the lead compound 2a by incorporating substituents into the 5-position or into both the 5- and 6-positions of the benzimidazole core part led to the identification of 5-(5-methyl-1,2,4-oxadiazol-2-yl)benzimidazole (2r: IC50 = 3.3 nM) and 5-(2-methyltetrazol-5-yl)benzimidazole (2u: IC50 = 5.9 nM), both of which are potent, selective, and orally bioavailable Y5 receptor antagonists. Crown Copyright

Novel spiro compounds

Compounds of the general formula (I): wherein Ar1 represents optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V, and W each independently represent nitrogen atom or optionally substituted methine group, where at least two of them represent the said methine group; X represents methine or hydroxy substituted methine; Y represents an optionally substituted imino or oxygen atom are described and claimed. These novel spiro compounds are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic diseases and the like.